IPO digital content under SEC Reg FD, FDA, and FINRA. Shares up 96%. Zero compliance incidents.

Digital content produced in connection with a public offering occupies one of the most heavily regulated positions in commercial communication. SEC Regulation FD prohibits the selective disclosure of material non-public information. Any digital content that touches on the company's clinical pipeline, financial position, or business prospects during the pre-IPO and IPO window must be reviewed against that prohibition before publication.

At the same time, CG Oncology is a healthcare company. Its products are subject to FDA regulation. Communications about oncology treatments, clinical trial results, and patient outcomes are subject to FDA advertising and disclosure requirements under 21 CFR Part 202. Content that would be permissible for a technology company at IPO may not be permissible for a biotech company subject to FDA oversight.

FINRA Rule 2210 adds a third layer. For broker-dealers and any entity whose communications are distributed through regulated channels, the rule sets standards for communications that include numerical performance claims or projections. Where digital content references clinical outcomes or financial metrics, FINRA Rule 2210 review applies.

These three frameworks operate simultaneously. They do not resolve each other's ambiguities. Content that clears FDA review may raise Reg FD questions. Content that satisfies FINRA communications standards may still fail FDA substantiation requirements. The review process had to address all three in a single pass, not sequentially.

Every content deliverable was mapped against all three frameworks before production began. The review protocol identified the specific claim types present in each piece: clinical outcome references, pipeline descriptions, financial projections, and biographical content for the leadership team. Each claim type carried its own applicable standard.

Clinical content was reviewed against FDA disclosure requirements first. Reg FD review covered any content that could be characterised as disclosure of material information about the business. FINRA Rule 2210 review applied to any content containing numerical claims. Where a piece contained claims across multiple categories, the most restrictive applicable standard governed.

The content architecture was built to be defensible: each published claim was documented with its substantiation source, the standard under which it was reviewed, and the reviewer's determination. The documentation was prepared for potential regulatory review, not merely as an internal record.

Zero compliance incidents across the listing process. No content was required to be withdrawn, amended, or corrected post-publication. No SEC, FDA, or FINRA enquiry arose from the digital content produced in connection with the IPO.

CG Oncology listed on Nasdaq as CGON. Shares were up 96% at IPO. The compliance record and the market outcome are both a function of the same discipline: content that is built to survive scrutiny is content that supports the proposition being made.